New study and promising results from the first clinical trial in patients provide novel insights and new hope for one of the deadliest of cancers. Gastric cancer remains a formidable adversary, ...
Eli Lilly and Co. has received the U.S. Food and Drug Administration’s breakthrough therapy designation for a drug in development to treat certain ovarian cancer patients. The Indianapolis-based ...
Gastric cancer remains a formidable adversary, ranking as the fifth most common cancer and the third-leading cause of cancer-related deaths worldwide, with over 1,000,000 new cases and close to ...
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...
Gastric cancers commonly spread to the peritoneum. Its presence significantly alters patient prognosis and treatment-intent; however, current methods of peritoneal staging are inaccurate. Peritoneal ...
NEW YORK, Nov. 18, 2025 /PRNewswire/ -- The DeGregorio Family Foundation with support from the Torrey Coast Foundation has awarded a $500,000 Michael F. Price Memorial Grant to Katy Rezvani, MD, PhD, ...
Image Caption: Proteomic alterations in post-NACT OCPM tissues. Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results